Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history

Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history

Abstract Background Japanese guidelines recommend triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) and no concurrent asthma diagnosis who experience frequent exacerbations...

Full description

Bibliographic Details
Main Authors: Shigeo Muro, Tomotaka Kawayama, Hisatoshi Sugiura, Munehiro Seki, Elizabeth A. Duncan, Karin Bowen, Jonathan Marshall, Ayman Megally, Mehul Patel
Format: Article
Language:English
Published: BMC 2024-08-01
Series:Respiratory Research
Subjects:
Blood eosinophils
Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF)
Chronic obstructive pulmonary disease (COPD)
Disease severity
Exacerbation rates
Lung function
Online Access:https://doi.org/10.1186/s12931-024-02918-8

Internet

https://doi.org/10.1186/s12931-024-02918-8

Similar Items